NGMDF (NuGen Medical Devices) Debt-to-Equity: -1.17 (As of Mar. 2026)


What is NuGen Medical Devices Debt-to-Equity?

NuGen Medical Devices NGMDF Debt-to-Equity is -1.17 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 706 Medical Devices & Instruments companies, NuGen Medical Devices ranks worse than 141642.92% on this metric.

NuGen Medical Devices's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $2.23 Mil. NuGen Medical Devices's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $10.79 Mil. NuGen Medical Devices's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-11.18 Mil. NuGen Medical Devices's debt to equity for the quarter that ended in Mar. 2026 was -1.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NuGen Medical Devices's Debt-to-Equity or its related term are showing as below:

NGMDF' s Debt-to-Equity Range Over the Past 10 Years
Min: -61.07   Med: -2.82   Max: 11.11
Current: -1.17

During the past 6 years, the highest Debt-to-Equity Ratio of NuGen Medical Devices was 11.11. The lowest was -61.07. And the median was -2.82.

NGMDF's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.225 vs NGMDF: -1.17

NuGen Medical Devices  (OTCPK:NGMDF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


NuGen Medical Devices Debt-to-Equity Related Terms


NuGen Medical Devices Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for NuGen Medical Devices's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NuGen Medical Devices Debt-to-Equity Chart

NuGen Medical Devices Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial 3.38 -3.27 -3.83 -3.14 -1.27

NuGen Medical Devices Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 -2.62 -2.12 -1.27 -1.17

NGMDF vs ABT, SYK, MDT: Debt-to-Equity Comparison

For the Medical Devices subindustry, NuGen Medical Devices's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NuGen Medical Devices Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NuGen Medical Devices's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NuGen Medical Devices's Debt-to-Equity falls into.



NuGen Medical Devices Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NuGen Medical Devices's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

NuGen Medical Devices's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -1.17 mean?
NuGen Medical Devices (NGMDF) has a Debt-to-Equity of -1.17 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NuGen Medical Devices and its competitors. According to the industry distribution chart, NuGen Medical Devices ranks #999999 out of 706 companies in the Medical Devices & Instruments industry.
Is NuGen Medical Devices' Debt-to-Equity too high?
NuGen Medical Devices' current Debt-to-Equity is -1.17. Based on the distribution chart, NuGen Medical Devices ranks #999999 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does NuGen Medical Devices' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NuGen Medical Devices ranks #999999 out of 706 companies for Debt-to-Equity. This places NuGen Medical Devices in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NuGen Medical Devices and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NuGen Medical Devices's current Debt-to-Equity is -1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NuGen Medical Devices stock overvalued right now?
Based on GuruFocus' analysis, NuGen Medical Devices (NGMDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 21.8% below its estimated fair value. The current Debt-to-Equity is -1.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For NuGen Medical Devices (NGMDF), the current Debt-to-Equity is -1.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NuGen Medical Devices Business Description

Other Exchanges 79O:GermanyNGMD:Canada
Address 18 King Street East, Suite 1400, Toronto, ON, CAN, M5C 1C4
NuGen Medical Devices Inc is a medical device manufacturing company specializing in the field of needleless injections and related technologies. The reportable segment of the company is the manufacturing of needle injector devices. Geographically, the company generates revenue from Europe, followed by Asia, and other.